Ouanterix The Science of Precision Health

Earnings Call Q2 2019 August 6, 2019



This presentation contains "forward-looking" statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.






- I. Strategic and Financial Progress Kevin Hrusovsky Chairman, CEO
 - i. Company Direction & Q2 Highlights
 - ii. Progress against 2019 Goals & Priorities
 - iii. Transforming Medicine: Neurology Momentum Update
- II. Financial Report Amol Chaubal CFO
- III. Summary of QTRX Opportunity Kevin Hrusovsky
- IV. Q&A

Disruptive Market, Technology and Growth




- Q2 Revenue \$13.5M, 57% growth; 60% growth 1H
- Q2 GM 51.2% versus 46.0% last yr; 580 bps increase 1H
- Added CFO, General Counsel and three commercial leaders
- Acquired Uman Diagnostics AB, world leader Nf-L antibody supplier
- Announced launch of the Simoa HD-X and SP-X Analyzers
- New world HQ's and center for biomarker innovation
- Strong showing at AAIC and momentum for Ectrims
- Strong growth of publications and new biomarkers



Q2 2019 Growth Led by Consumables and Services





Lab. &

Other Services

Total Gross Margin 50%, +580 bps ٠

5.7

7.5

12.2

33%


29%

Transforming Medicine with Digital Biomarkers




Today : Invasive & Late

Tomorrow : Non-Invasive & Early



Simoa Sees Health to Disease Continuum






Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 7

Strategic Direction Remains Unchanged Capture major market opportunity through our disruptive technology






D. R., Duffy, D. C., 2010. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations, Nat. Biotechnol., 28, 595.


1H 2019 Growth Stratification





Scientific Research is Driving Brand Awareness, Performance and Utilization





* Cumulative


Quanterix Product Offerings



Instruments			Assay kits	Services	
		Quanterix SP-X SP-X			
HD-X	SR-X	SP-X	Plate Bead	Accelerator	
Floor-standing integrated	Benchtop semi-	Simoa planar assay	300+ assays	Contract research & testing	
Assay prep and detection	automated assay prep	Benchtop semi- automated assay prep	Homebrew kits	Custom assay development & reagent production CLIA and LDT capabilities	
Major performance improvements over HD-1		Multiplex capabilities	Singleplex and Multiplex		
550+ publications					

Competitive Landscape





Objectives 2019 Large strides in Q2 towards securing our 2019 objectives



		STRATESY		
Neurology <10% Penetrated	Oncology 3x Neuro	Strategy Dx via Biopharma	Financials	Technology
High double digit growth with high utilization Add 25 assays and globalize	Launch penetration in Oncology market Immuno therapy focus	LDT/IVD partnerships 50 phase I, II, III trials M&A: Ab's, Clinical Lab	LT Growth: 40% Gross Margin: +300 bps Instrument Growth: +25%	100x incremental sensitivity by YE 2021 New frontier of medicine Protein Translational Modifications
 Taking HD-X orders, shipping first units by end Q3 ahead of schedule 	 Launched SPX Q2'19 High utilization, early launch success 	 Clinically validate Nf-L for 2nd'ary endpoint & DP Uman / partnerships 	 1H revenue growth +60% 1H gross margin +580 bps 1H Inst growth +62% 	 40X defined Prototype developed


We are Addressing a Significant Unmet Need in Drug Development FDA Announces Office of Drug Evaluation Science - ODES



DRUG PERFORMANCE	PROBABILITY OF DRUG APPROVAL	VALIDATION OF SIMOA IMPACT	
TOXICITY Adverse drug events are a substantial cause of Death in USA	300% increase if biomarkers are used	Simoa'S at CROs Trials at Quanterix 32	
EFFICACY	Hematology 26.1%		
Depression 62%	Infectious disease 19.1%	2 0	
Schizophrenia 60%	Metabolic 15.3%	2015 2018 2015 2018	
Cardiac arrhythmia 60%	Gastroenterolgy 15.1%	650 clinical trials	
Asthma 60%	Autoimmune 11.1% O.4 ⁷⁰ Goes to	with Simoa at single CRO	
Diabetes 57%	All indications 9.6% 25%	400 PHASE I	
Osteoporosis 48%	Neurology 8.4% Approval		
Hepatitis C 47%	Cardiovascular 6.6% after PHASE I	200 PHASE II	
AD 30%	Oncology 5.1%	50 PHASE III	
Cancer 25%	Probability of phase III approval after Phase 1 approval	MYRIAD • RBM.	

Unmet Need

Development of neurological disease diagnostics has been slow due to disease complexity



Neuro health has become national Health Priority due to veteran PTSD, opioid addictions, AD demographics,mental health issues, and healthcare burden of neurological conditions

Biopharma industry discouraged by lack of returns and use of subjective cognitive endpoints T

FDA issuing guidance to enable use of biomarkers in drug trials for early stage disease cohorts

2

Biopharma deploying biomarker approaches to trial design

Source: Health Advances analysis, Quanterix materials.


Ouante

The Science of Precision Hea

Blue Chip Customers 2019

PROFILE SCIENCE, HOP







Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 16

Strategic Roadmap Moving Biomarkers from Analytical Validity to Clinical Validity











Uman Nf-L Antibody is unparalleled







NFL PUBLICATIONS




STUDIES CONFIRM NFL CLINICAL UTILITY:

- Disease activity monitoring
- Drug efficacy monitoring
- Relapse/severity prognostic

Majority of published data obtained with Simoa NfL

WW DISEASE INCIDENCE (MILLIONS)



MULTIPLE SCLEROSIS:

- Avg. age of onset: 34 yrs; avg. life expectancy after onset: 30 yrs
- Standard of care: MRI 1-2X/yr
- NfL as MRI replacement: 3.5M tests/yr

Clinical Validation of NfL for MS is a Key Beachhead

Acquisition of Uman Diagnostics | June 26, 2019 | 20

Digital Biomarkers Disruption Paradigm Alzheimer's Disease Opportunity





Alzheimer's disease not diagnosed until symptoms



Imaging expensive and often not covered



Therapies for later stage disease have limited effectiveness



Detect or screen in annual blood test







Therapy delivered sooner with less dosing / toxicity. Blood test monitors progression



Aducanumab from Biogen

Pattern of AD Drug Failure – Is there Hope? Roche, Biogen, Amgen, Novartis halting trials early



Can early detection

enable AD drug

rescue?

Biotech

Roche halts phase 3 anti-Abeta Alzheimer's test as AD flops rack up

by Nick Paul Taylor | Jan 30, 2019 7:41am

BIOTECH

STAT+

Biogen halts studies of closely watched Alzheimer's drug, a blow to

hopes for new treatment

By ADAM FEUERSTEIN @adamfeuerstein / MARCH 21, 2019



FierceBiotech

RESEARCH CRO MEDTECH BIOTECH

Biotech

Weak data spur Amgen, Novartis to can pivotal Alzheimer's test

by Nick Paul Taylor | Jul 12, 2019 8:30am

Amgen and Novartis halt Alzheimer's

March 2019

Jan 2019

July 2019

MARKETS BUSINESS INVESTING TECH POLITICS CNBC TV

BIOTECH AND PHARMA

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

PUBLISHED FRI, MAR 22 2019 • 6:46 AM EDT | UPDA




Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 22


Q2 2019 & 1H 2019 Financials



in \$m	Q2 2019	Q2 2018	1H 2019	1H 2018
Product Revenue	8.8	5.2	18.3	9.9
Growth vs. PYR	69%		84%	
Service Revenue	4.8	3.2	7.5	5.7
Growth vs. PYR	50%		33%	
Collaboration Revenue	0.0	0.3	0.0	0.5
Total Revenue	13.5	8.6	25.9	16.2
Growth vs. PYR	57%		60%	
Gross Profit	6.9	4.0	12.9	7.1
Gross Margin %	51.2%	46.0%	50.0%	44.2%
Operating Expenses	17.4	11.3	32.8	21.6
Loss from operations	-10.5	-7.3	-19.9	-14.5



\$m Q2 2019 Cash & Cash Flow (excl. Restricted Cash)



Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 23

Poised to Disrupt Healthcare and Create Significant Value



	Differentiator	Value
1 Category-defining; Unrivaled Sensitivity / Technology	Best in Class	Disrupt
Methodical market penetration strategy to reward investors	\$3B to \$40B	New Answers
3 DNA – RNA - Protein; Better linked to Disease / Health		Holy Grail
Quanterix 4 Validation: 19/20 top pharma, PPH, 800+ trials	550+ pubs All Areas	Proven
Execution 5 Growth & Value; Razor – razor blade, \$150M invested	Product Launches	Rapid Growth
6 Low Risk / Solid Return + Uber Return Prospect		Retail
7 Track Record for Commercializing Disruption		Lynchpin